All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Abbvie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
Singapore’s HSA approves belantamab mafodotin combinations for RRMM
On August 19, 2026, the Singapore Health Sciences Authority (HSA) approved belantamab mafodotin, a B-cell maturation antigen (BCMA)-directed antibody–drug conjugate, in combination with bortezomib + dexamethasone (BVd) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) after ≥1 prior line of therapy, and in combination with pomalidomide + dexamethasone (BPd), for the treatment of patients with RRMM after ≥1 prior line of therapy including lenalidomide.
These approvals were based on data from the pivotal phase III DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials, respectively. Data from these trials have been reported previously on the Multiple Myeloma Hub.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
